InO is currently tested in front-line treatment by the COG in a phase III randomized trial for high-risk CD22-positive BCP-ALL (NCT03959085), and in the ALLTogether1 protocol, for patients stratified to the intermediate-high risk group (NCT03911128). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.